View as an RSS Feed
View Cory Renauer's Articles BY TICKER:
ABX, ACOR, AEGR, ALNY, ALXN, AMGN, AMRI, ANAC, ANIK, ARIA, BAX, CBST, CELG, CERS, CHK, CLNE, CMCSA, CMI, CNDO, CRTX, CYTX, DDD, EBS, ENTA, EOPN, EXEL, FCX, FOLD, GG, GILD, GIS, HFC, IDIX, INFI, ISIS, ITMN, JCP, LLY, LNG, LNKD, MDT, MGNX, MNKD, MNTA, MRVL, MYGN, NEM, NPSP, NSPH, PFE, PPHM, SGMO, SQNM, SRPT, UTHR, WMGI, WPRT, XNPT
2 Huge Immunology Opportunities For Celgene
- All oral Otezla ready to take on psoriasis by end of year.
- Oral Otezla won’t entirely displace injected biologics, but safety and convenience should easily push it over the $1 billion mark.
- Early clinical data suggests oral antisense drug GED-0301 could be a Crohn’s disease winner.
Aspire Data A Big Plus For Amgen And Celgene
- Progression free survival figures could result in Kyprolis/Revlimid/dexamethasone becoming standard of care for advanced multiple myeloma.
- Lack of adverse events alleviates cardiovascular event fears.
- Celgene also stands to gain from increased duration of Revlimid use.
Momenta Pharmaceuticals Heading For A Repeat
- Momenta's success with generic Lovenox is a strong indication of potential success with generic Copaxone.
- Beyond Copaxone, characterization capabilities could differentiate Momenta from competition.
- If advantages associated with its proprietary technology don’t materialize, Momenta could be in big trouble.
- A modified anticoagulant with anti-tumor properties also has blockbuster potential.
- Patent And Reimbursement Risks Already Priced In At Myriad Genetics
- Diabetes Programs Now Crucial For Eli Lilly
- Undervalued Baxter Is A Great Opportunity For Long-Term Dividend Growth Investors
- The 'Breakthrough Therapy' Designation And Alexion's CPMP Program
- Medtronic Growth Drivers For The Years Ahead
- Enanta's Abbvie Partnership Is Going Places But It's Still Overvalued
- MacroGenics Climbing The MAB Ladder With A Safety Net
- Xenoport: One Door Closed, Two More Opened
- Emergent Biosciences Finally Expanding Beyond Anthrax
- Cornerstone Therapeutics: Ignored And Clearly Undervalued
- Albany Molecular's Turnaround Train Is Gaining Steam
- Anacor's Future Is Positive Despite Tavaborole Issues
- Dark Days Ahead For Amicus, Reasons You Shouldn't Fold
- NPS Pharmaceuticals Has A Billion Plus Blockbuster On Its Hands
- Aegerion's Lomitapide Launch Progressing Better Than Expected
- Cerus Corp.'s Intercept Blood System Progress Report
- Sequenom Billing Code Drama An Opportunity For Long-Term Investors
- United Therapeutics Reports Record Earnings, Guides Higher, And Is Still Cheap
- InterMune Successfully Entering Huge Niche Market Unchallenged
- Cubist Pharmaceuticals: Doomsday Preparation Update
- Peregrine Pharmaceuticals: Good Looking, But Still Single
- Putting Alnylam's Positive ATTR Clinical Data In Context
- Cytori Therapeutics Using Your Fat To Heal Your Heart
- A Closer Look At Acorda's Post Commercial Stage Strategy
- Sangamo Engineering Genetic Cures
- Coronado Biosciences Reuniting Old Friends
- Nanosphere: There's Gold In Its Diagnostic Tools
- Wright Medical Group Making Bold Moves
- Alnylam's 5x15 Progress Report